-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
First API Approval of the Year! Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical Receives Marketing Approval for Benidipine Hydrochloride API
Category:
TIME：2025-01-07
At the start of the new year, on January 6, the benidipine hydrochloride API submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved to be upgraded to “A,” making it the group’s first newly approved API variety in 2025.
To date, the Group has been granted approval for a total of 68 active pharmaceutical ingredient (API) products, with Guangxiang Pharmaceutical accounting for 38 of these approvals.
According to available information, benidipine hydrochloride API is a calcium channel blocker primarily indicated for the treatment of primary hypertension and angina pectoris. The approval of this product as an API for marketed dosage forms will further expand the Group’s portfolio of specialty APIs and support the deeper integration of “APIs plus formulations” across the value chain.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
